ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC

ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC

Immunotherapy by immune checkpoint inhibitors (ICIs) has showed outstanding efficacy in the treatment of advanced non-small cell lung cancer (NSCLC). The combination of immunotherapy with anti-angiogenic therapy exhibited enhanced efficacy in multiline treatment. However, the potential biomarkers fo...

Full description

Bibliographic Details
Main Authors: Yao Chen, Xiaobin Li, Guifeng Liu, Shifu Chen, Mingyan Xu, Lele Song, Yina Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Oncology
Subjects:
NSCLC
immunotherapy
PD-1
angiogenic
ctDNA
TMB
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01706/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.01706/full

Similar Items